| Abstrakt: |
A recent study conducted by the University of Pretoria in South Africa compared the effects of two antiretroviral therapies, efavirenz (EFV) and dolutegravir (DTG), on individuals living with HIV. The study found that transitioning from EFV to DTG resulted in changes in metabolic and inflammatory markers, as well as platelet activation, that were similar to those observed in HIV-negative individuals. The researchers concluded that the transition to DTG-based regimens may have potential benefits for individuals living with HIV, as it could help reduce the risk of chronic non-AIDS-related diseases. Further research is needed to fully understand the impact of this treatment transition. [Extracted from the article] |
